Metropolis Healthcare Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Healthcare Services | Market Cap: ₹11.3K Cr
Organic revenue growth target for FY '26 is 12% to 13%, with ambition to hit the higher end of the range. The company aims for mid- to high single-digit patient volume growth (7% to 8%) in the near future, supported by ongoing programs.
From Metropolis Healthcare Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹557
Market Cap
₹11.3K Cr
P/E Ratio
54.4
How does Metropolis Healthcare Ltd rank in Healthcare Services?
Compare Metropolis Healthcare Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Metropolis Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹425 Cr, net profit ₹51 Cr.
Full financials →📊 Revenue & Sales Performance
- →Organic revenue growth target for FY '26 is 12% to 13%, with ambition to hit the higher end of the range.
- →Q3 delivered a strong 15% organic revenue growth; the company expects improved top-line performance in Q4.
- →Patient volume growth is targeted at 7% to 8% in the near future, supported by early success in growth programs.
- →Test volume grew 8% organically in Q3, reflecting expanding contribution from wellness and specialty segments.
- →Expansion in Tier 2 and Tier 3 cities through franchise channels is expected to drive consistent volume growth.
- →Growth in specialty and advanced diagnostic tests, including genomics, is anticipated to be a key driver over the next 10 years.
- →The company is focused on deepening B2B institutional partnerships to stabilize and grow demand predictably.
- →Future capex guidance is currently not disclosed but will be shared later; strategic network consolidation continues progressively.
📈 Profitability & Margins
- →The company aims for mid- to high single-digit patient volume growth (7% to 8%) in the near future, supported by ongoing programs.
- →Organic revenue growth target for FY '26 is 12% to 13%, with an aspiration to reach the higher end of this range.
- →EBITDA margin expansion continues, driven by material cost efficiencies, operating leverage, and productivity initiatives; organic EBITDA margin stood robust at about 25%.
- →Core Diagnostics margins are expected to reach high single-digit as an exit run rate by Q4 FY '26.
- →PAT, excluding exceptional items, grew strongly (52% YoY for organic), with PAT margin expansion of approximately 300 bps, indicating improving operating profitability.
- →The labor code impact of around INR 5-6 crores is recurring but manageable relative to overall earnings.
- →The company plans to provide next year’s strategic and earnings guidance by end of Q4.
- →Overall confidence expressed in margin expansion and sustained revenue growth driven by specialty and TruHealth segments.
🏗️ Capital Expenditure Plans
- →Capex guidance for the 9-month period is approximately INR 40 crores; expected full-year capex around INR 60 crores (Page 15).
- →Capex primarily directed towards strengthening and expanding the pan-India lab and collection center network, upgrading IT systems, processes, and scaling up high-end equipment for advanced and super-specialty test capabilities (Page 9).
- →Aspirational target to improve collection centers (CC) per lab ratio from ~20-22 to around 30 centers per lab; timeline not fixed, gradual progression focused on consolidation and expansion (Page 17).
- →No specific capex guidance provided for the next 2 years at this time; management may share details later (Page 17).
- →Strategic investments include the establishment of Centre of Genomics as a national reference hub, supported by CAP-accredited labs to drive growth in advanced molecular testing (Page 6).
💰 Fundraising & Capital Structure
- →The transcript does not mention any current or planned fundraising efforts through debt or equity.
- →The company reports a net debt-free position with cash reserves of INR 127 crores.
- →No guidance or comments were provided regarding raising funds via debt or equity during the call.
- →Focus appears to be on organic growth and using accumulated cash reserves to fund future growth initiatives.
- →The management emphasizes strengthening and expanding pan-India network and upgrading IT systems funded from internal accruals.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Metropolis Healthcare Ltd Q3 FY26 results?
Organic revenue growth target for FY '26 is 12% to 13%, with ambition to hit the higher end of the range. The company aims for mid- to high single-digit patient volume growth (7% to 8%) in the near future, supported by ongoing programs.
What is Metropolis Healthcare Ltd share price analysis?
Metropolis Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 54.4 with a market cap of ₹11,313 Cr. Investors should review the full earnings analysis for detailed insights.
Is Metropolis Healthcare Ltd planning capital expenditure?
Capex guidance for the 9-month period is approximately INR 40 crores; expected full-year capex around INR 60 crores (Page 15).
Keep Metropolis Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.